Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.

Trial Profile

Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2013

At a glance

  • Drugs Mesalazine (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms MOTUS
  • Most Recent Events

    • 14 Feb 2013 Results from a subanalysis of data from this trial have been presented at the Congress of European Crohn's and Colitis Organisation according to a Ferring Pharmaceuticals media release. Results were also summarised in the media release.
    • 22 May 2012 Results presented at the Digestive Disease Week 2012.
    • 22 May 2012 Results presented at Digestive Disease Week 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top